Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., . . . Mannel, R. S. (2017). Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 18(6), 779-791. https://doi.org/10.1016/S1470-2045(17)30279-6
Chicago-Zitierstil (17. Ausg.)Coleman, Robert L., et al. "Bevacizumab and Paclitaxel–carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet Oncology 18, no. 6 (2017): 779-791. https://doi.org/10.1016/S1470-2045(17)30279-6.
MLA-Zitierstil (9. Ausg.)Coleman, Robert L., et al. "Bevacizumab and Paclitaxel–carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet Oncology, vol. 18, no. 6, 2017, pp. 779-791, https://doi.org/10.1016/S1470-2045(17)30279-6.